What the quality statement means for service providers, healthcare professionals and commissioners .. Sickle cell disease (QS58)
Introduction Introduction
This quality standard covers the management of sickle cell acute painful episode in people in hospital from the time of presenting to hospital until the time of discharge. For more information see the topic overview.
Why this quality standard is needed
Sickle cell disease is the name given to a group of lifelong inherited conditions that affect haemoglobin. Most people affected are of African or African-Caribbean origin, although the sickle gene is found in all ethnic groups. It is estimated that there are between 12,500 and 15,000 people with sickle cell disease in the UK [1] . The prevalence of the disease is increasing because of immigration into the UK and new births.
Acute painful sickle cell episode (also known as painful crisis) is an acute condition that occurs in people with sickle cell disease. In these people red blood cells behave differently under a variety of conditions, including dehydration, low oxygen levels and elevated temperature. Changes in any of these conditions may cause the red blood cells to block the small blood vessels, restricting blood flow. This damages the tissue, which causes pain.
Acute painful sickle cell episodes occur unpredictably, often without clear precipitating factors.
Their frequency may vary from less than 1 episode a year to severe pain at least once a week. Pain can vary in both intensity and duration, and may be excruciating.
Most painful episodes are managed at home, with people usually seeking hospital care only if the pain is uncontrolled or they have no access to analgesia. The primary goal in the management of an acute painful sickle cell episode is to achieve effective pain control both promptly and safely. The management of acute painful sickle cell episodes for people presenting at hospital is variable throughout the UK, and is a frequent source of complaints.
How this quality standard supports delivery of outcome frameworks
NICE quality standards are a concise set of prioritised statements designed to drive measureable Sickle cell disease (QS58) quality improvements within a particular area of health or care. They are derived from high-quality guidance, such as that from NICE or other sources accredited by NICE. This quality standard, in conjunction with the guidance on which it is based, should contribute to the improvements outlined in the following outcomes framework published by the Department of Health:
NHS Outcomes Framework 2014-15 Table 1 show the outcomes, overarching indicators and improvement areas from the framework that the quality standard could contribute to achieving.
T 
Coordinated services
The quality standard for sickle cell acute painful episode specifies that services should be commissioned from and coordinated across all relevant agencies encompassing the whole sickle cell acute painful episode pathway. A person-centred, integrated approach to providing services is fundamental to delivering high-quality care to people with a sickle cell acute painful episode. Quality statement 1: Timely assessment and analgesia Quality statement 1: Timely assessment and analgesia
Quality statement
People who present at hospital with an acute painful sickle cell episode have a pain assessment, a clinical assessment and appropriate analgesia within 30 minutes of presentation.
Rationale
A thorough and rapid assessment at presentation is needed to ensure that people with an acute painful sickle cell episode have an accurate diagnosis. Pain assessment should be performed using an age-appropriate pain scoring tool. This ensures that adequate analgesia is given and will inform future management. If acute pain is not recognised and adequate analgesia is not given promptly, the pain may escalate, causing unnecessary distress and deterioration in the person's condition.
Quality measures
Structure Structure
Evidence of local arrangements to ensure that people who present at hospital with an acute painful sickle cell episode have a pain assessment, a clinical assessment and appropriate analgesia within 30 minutes of presentation. Sickle cell disease (QS58) b) Proportion of people who present at hospital with an acute painful sickle cell episode who have their pain assessed using an age-appropriate pain scoring tool.
Data sour
Numerator -the number of people in the denominator who have their pain assessed using an ageappropriate pain scoring tool.
Denominator -the number of people who present at hospital with an acute painful sickle cell episode. 

What the quality statement means for service providers, healthcare professionals and commissioners
Service pro Service providers viders ensure that they have sufficient resources to assess both pain and clinical signs in people who present at hospital with an acute painful sickle cell episode and to give appropriate analgesia within 30 minutes of presentation.
Healthcare professionals Healthcare professionals ensure that they assess both pain and clinical signs in people who present at hospital with an acute painful sickle cell episode and give appropriate analgesia within 30 minutes of presentation.
Commissioners Commissioners ensure that they commission services that have sufficient resources to assess both pain and clinical signs in people who present at hospital with an acute painful sickle cell episode and give them appropriate analgesia within 30 minutes of presentation.
What the quality statement means for patients, service users and carers
P People eoplewho go to hospital with a painful attack of sickle cell disease who go to hospital with a painful attack of sickle cell disease (acute painful sickle cell episode) have their pain, blood pressure, blood oxygen levels, heart rate, breathing rate and temperature checked, and are given the right amount of pain relief within 30 minutes of arriving.
Source guidance
Sickle cell acute painful episode (NICE clinical guideline 143), recommendations 1.1.3, 1.1.4 and 1.1.5.
Sickle cell disease (QS58)
Definitions of terms used in this quality statement P Pain assessment ain assessment A pain assessment should assess the severity of pain using an age-appropriate pain scoring tool.
[NICE clinical guideline 143, recommendation 1. 
Equality and diversity considerations
Most people with sickle cell disease are of African or African-Caribbean origin. This may mean that language needs to be taken into account when deciding on the type of pain scoring tool to be used.
Age, especially if the person is a young child, and any physical, sensory or learning disabilities also need to be taken into account.
In young children, people with learning disabilities and people in great pain, it may not be possible to determine the cause of the pain initially without a fuller examination.
Sickle cell disease (QS58)
Quality statement 2: Regular assessment of pain relief Quality statement 2: Regular assessment of pain relief
Quality statement
People with an acute painful sickle cell episode have an assessment of pain relief every 30 minutes until satisfactory pain relief has been achieved and then at least every 4 hours.
Rationale
Assessment of pain relief is important for determining the effectiveness of the analgesia given at the time of presentation. It is also important for ensuring that more painkillers are given when
needed until the episode has ended or the patient is discharged. Using an age-appropriate pain scoring tool ensures consistency when assessing pain and helps healthcare professionals to ensure that pain relief is appropriate.
Quality measures
Structure Structure Numerator -the number of people in the denominator who have their pain relief reassessed using an age-appropriate pain scoring tool.
Denominator -the number of people with an acute painful sickle cell episode.
Data sour
Data source: ce:Local data collection.
What the quality statement means for service providers, healthcare professionals and commissioners
Service pro Service providers viders ensure that they have sufficient resources to reassess pain relief in people with an acute painful sickle cell episode every 30 minutes until satisfactory pain relief has been achieved and then at least every 4 hours until discharge or the end of the episode.
Healthcare professionals Healthcare professionals ensure that they reassess pain relief in people with an acute painful sickle cell episode every 30 minutes until satisfactory pain relief has been achieved and then at least every 4 hours until discharge or the end of the episode.
Commissioners Commissioners ensure that they commission services that have sufficient resources to reassess pain relief in people with an acute painful sickle cell episode every 30 minutes until satisfactory pain relief has been achieved, and then at least every 4 hours until discharge or the end of the episode.
Sickle cell disease (QS58)
What the quality statement means for patients, service users and carers P People eoplewith a painful attack of sickle cell disease with a painful attack of sickle cell disease (acute painful sickle cell episode) have their pain relief checked every 30 minutes until they are comfortable and then at least every 4 hours until they leave hospital or their episode has ended.
Source guidance
Sickle cell acute painful episode (NICE clinical guideline 143), recommendation 1.1.12. 
Definitions of terms used in this quality statement
Equality and diversity considerations
Sickle cell disease (QS58)
Quality statement 3: Strong opioids and monitoring Quality statement 3: Strong opioids and monitoring
Quality statement
People with an acute painful sickle cell episode who are taking strong opioids are monitored for adverse events every hour for the first 6 hours after first administration or step up of pain relief and then at least every 4 hours.
Rationale
Monitoring for adverse events in people with an acute painful sickle cell episode who are taking strong opioids is important to ensure patient safety. Monitoring is initially done hourly because the risk of adverse events is higher in the first 6 hours after first administration or a step up of pain relief.
Quality measures
Structure Structure
Evidence of local arrangements to ensure that people with an acute painful sickle cell episode who are taking strong opioids have monitoring for adverse events every hour for the first 6 hours after first administration or step up of pain relief and then at least every 4 hours.
Data sour
Data source: ce: Local data collection.
Process Process a) Proportion of people with an acute painful sickle cell episode taking strong opioids who are monitored for adverse events every hour for the first 6 hours after first administration or step up of pain relief.
Numerator -the number of people in the denominator who are monitored for adverse events every hour for the first 6 hours after first administration or step up of pain relief.
Denominator -the number of people with an acute painful sickle cell episode taking strong opioids.
Data sour Data source: ce: Local data collection.
Sickle cell disease (QS58) b) Proportion of people with an acute painful sickle cell episode taking strong opioids who have had hourly monitoring for adverse events for the first 6 hours after first administration or step up of pain relief and who are then monitored for adverse events at least every 4 hours until discharge or the end of the episode.
Numerator -the number of people in the denominator who are monitored for adverse events at least every hour 4 hours until discharge or the end of the episode.
Denominator -the number of people with an acute painful sickle cell episode taking strong opioids who have had hourly monitoring for adverse events for 6 hours following first administration or step up of pain relief.
What the quality statement means for service providers, healthcare professionals and commissioners
Service pro Service providers viders ensure that they have sufficient resources for people with an acute painful sickle cell episode who are taking strong opioids to be monitored for adverse events every hour for the first 6 hours after first administration or step up of pain relief and then at least every 4 hours until discharge or the end of the episode.
Healthcare professionals Healthcare professionals ensure that people with an acute painful sickle cell episode who are taking strong opioids are monitored for adverse events every hour for the first 6 hours after first administration or step up of pain relief and then at least every 4 hours until discharge or the end of the episode.
Commissioners Commissioners ensure that they commission services that provide sufficient resources for people with an acute painful sickle cell episode who are taking strong opioids to be monitored for adverse events every hour for the first 6 hours after first administration or step up of pain relief and then at least every 4 hours until discharge or the end of the episode.
What the quality statement means for patients, service users and carers
P People eoplewith a painful attack of sickle cell disease with a painful attack of sickle cell disease (acute painful sickle cell episode) who are taking strong painkillers (strong opioids) are checked for possible side effects every hour for the first 6 hours and then at least every 4 hours until they leave hospital or their episode has ended.
Sickle cell disease (QS58)
Source guidance
Sickle cell acute painful episode (NICE clinical guideline 143), recommendation 1.1.16. Step up of pain relief
Definitions of terms used in this quality statement
Step up of pain relief 
Quality statement
People with an acute painful sickle cell episode are assessed for acute chest syndrome if they have 1 or more of the following: abnormal respiratory signs or symptoms, chest pain, fever, or signs and symptoms of hypoxia.
Rationale
Acute chest syndrome is a major cause of morbidity and mortality in people with sickle cell disease.
It can progress rapidly and is not always recognised as a possible complication. Monitoring by clinical assessment, acting on any changes and assessing for acute chest syndrome may lead to this complication being identified and treatment started earlier.
Quality measures
Structure Structure a) Evidence of local arrangements to ensure that healthcare professionals caring for people with an acute painful sickle cell episode are aware of acute chest syndrome as a potential complication.
Data sour
b) Evidence of local arrangements to ensure that people with an acute painful sickle cell episode are assessed for acute chest syndrome if they have 1 or more of the following: abnormal respiratory signs or symptoms, chest pain, fever, or signs and symptoms of hypoxia.
Process Process
Proportion of people with an acute painful sickle cell episode with 1 or more of the following:
abnormal respiratory signs or symptoms, chest pain, fever, or signs and symptoms of hypoxia who are assessed for acute chest syndrome.
Numerator -the number of people in the denominator who are assessed for acute chest syndrome.
Denominator -the number of people with an acute painful sickle cell episode who have 1 or more Sickle cell disease (QS58) of the following: abnormal respiratory signs or symptoms, chest pain, fever, or signs and symptoms of hypoxia.
Data sour
What the quality statement means for service providers, healthcare professionals and commissioners
Service pro Service providers viders ensure that healthcare professionals caring for people with an acute painful sickle cell episode are aware of acute chest syndrome as a potential complication and that people with an acute painful sickle cell episode need to be assessed for acute chest syndrome if they have 1 or more of the following: abnormal respiratory signs or symptoms, chest pain, fever, or signs and symptoms of hypoxia.
Healthcare professionals Healthcare professionals ensure that they are aware of acute chest syndrome as a potential complication of an acute painful sickle cell episode and assess for acute chest syndrome if people have 1 or more of the following: abnormal respiratory signs or symptoms, chest pain, fever, or signs and symptoms of hypoxia.
Commissioners Commissioners ensure that they commission services that have staff trained to recognise acute chest syndrome as a potential complication of acute painful sickle cell episode and to assess for acute chest syndrome if people with an acute painful sickle cell episode have 1 or more of the following: abnormal respiratory signs or symptoms, chest pain, fever, or signs and symptoms of hypoxia.
What the quality statement means for patients, service users and carers
P People with a painful attack of sickle cell disease eople with a painful attack of sickle cell disease (acute painful sickle cell episode) who have any breathing problems, chest pain or fever are assessed for a serious lung condition called acute chest syndrome.
Source guidance
Sickle cell acute painful episode (NICE clinical guideline 143), recommendation 1.1.19.
Sickle cell disease (QS58)
Quality statement 5: Protocols and specialist support Quality statement 5: Protocols and specialist support
Quality statement
Healthcare professionals who care for people with an acute painful sickle cell episode have access to locally agreed protocols on treatment and management and specialist support from designated centres.
Rationale
The distribution of sickle cell disease varies throughout England; two-thirds of people with sickle cell disease live in London, and most others live in the other big cities. Therefore the demand for treatment and management of acute painful sickle cell episode differs across the country. To ensure high-quality care for all people with an acute painful sickle cell episode, healthcare professionals need to be able to access locally agreed protocols that set out treatment and management. They also need to know how to access specialist support from designated centres when needed.
Quality measures
Structure Structure a) Evidence of local arrangements to ensure that locally agreed protocols on how to treat and manage acute painful sickle cell episodes are available and reviewed regularly. 
Data sour
What the quality statement means for service providers, healthcare professionals and commissioners
Service pro Service providers viders ensure that locally agreed protocols for treating and managing acute painful sickle cell episodes are available and regularly reviewed, and that healthcare professionals who care for people with an acute painful sickle cell episode are aware of and have access to these protocols. Service providers ensure that healthcare professionals know how to access specialist support for sickle cell care from designated centres.
Healthcare professionals Healthcare professionals who care for people with an acute painful sickle cell episode ensure that they have access to locally agreed protocols on treatment and management and know how to access specialist support for sickle cell care from designated centres.
Commissioners Commissioners ensure that they commission services for people with an acute painful sickle cell episode, which have access to locally agreed protocols for treatment and management.
Commissioners should engage with local and specialist services to designate centres that can offer specialist support, and should ensure that the specialist centres have the resources to do this.
What the quality statement means for patients, service users and carers
P People with a painful attack of sickle cell disease eople with a painful attack of sickle cell disease (acute painful sickle cell episode) are cared for by healthcare professionals who can follow locally agreed procedures for managing the condition and can get support from specialist centres if needed.
Source guidance
Sickle cell acute painful episode (NICE clinical guideline 143), recommendations 1.1.1 and 1.1.25.
Sickle cell disease (QS58)
Quality statement 6: Discharge information Quality statement 6: Discharge information
Quality statement
People with an acute painful sickle cell episode are given information before discharge on how to continue to manage their current episode.
Rationale
People with an acute painful sickle cell episode who are discharged from hospital need written information on accessing specialist advice, managing side effects of treatment and obtaining additional medication. This applies to everyone whether they are still taking strong opioids at the time of discharge or whether the episode ended while they were in hospital. Because sickle cell disease is a rare condition everyone should have this information so that they can discuss their needs with other healthcare professionals who are involved in continuing care.
Quality measures
Evidence of local arrangements to ensure that people with an acute painful sickle cell episode are given information before discharge on how to continue to manage their current episode.
Data sour
Process Process
Proportion of people with an acute painful sickle cell episode (or their parents or carers if appropriate) who are given information before discharge on how to continue to manage their current episode.
Numerator -the number of people in the denominator (or parents or carers if appropriate) who are given information on how to continue to manage their current episode.
Denominator -the number of people with an acute painful sickle cell episode who are discharged from hospital. Commissioners and providers should aim to achieve the quality standard in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity and foster good relations. Nothing in this quality standard should be interpreted in a way that would be inconsistent with compliance with those duties.
Data sour
Sickle cell disease (QS58)
De Dev velopment sources elopment sources
Further explanation of the methodology used can be found in the quality standards Process guide on the NICE website.
Evidence sources
The documents below contain recommendations from NICE guidance or other NICE-accredited recommendations that were used by the Quality Standards Advisory Committee to develop the quality standard statements and measures.
Sickle cell acute painful episode. NICE clinical guideline 143 (2012).
Definitions and data sources for the quality measures
Sickle cell acute painful episode: clinical audit tool. NICE clinical guideline 143 (2012). 
